Decreased short- and long-term swallowing problems with altered radiotherapy dosing used in an organ-sparing protocol for advanced pharyngeal carcinoma

Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):831-6. doi: 10.1001/archotol.130.7.831.

Abstract

Objective: To determine the effect of a reduced radiotherapy dose on short- and long-term swallowing problems after organ-sparing treatment.

Design: Prospective case series.

Setting: Tertiary care referral center.

Patients: A consecutive sample of 29 patients with advanced oropharyngeal or hypopharyngeal cancer who were treated with intravenous hydroxyurea and concomitant hyperfractionated, accelerated radiotherapy.

Interventions: Initial experience with 74.4 Gy of radiation demonstrated severe long-term swallowing problems, prompting a dose reduction to 60.0 Gy. Eighteen patients were followed up for this study in the 74.4-Gy group, while 11 were in the 60.0-Gy group.

Main outcome measures: Swallowing variables were assessed in both patient groups at 4 months and at 12 months following completion of therapy.

Results: Patient demographics and tumor characteristics were similar in each group, while significant differences were noted in the posttreatment clinical swallowing variables. Persistent severe odynophagia at 4 months (89% [16/18] vs 30% [3/10]) and at 12 months (64% [7/11] vs 11% [1/9]) was greater in the 74.4-Gy group (P =.002). Clinical signs of aspiration were also increased in the 74.4-Gy group, with 81% (13/16) vs 11% (1/9) at 4 months and 60% (6/10) vs 11% (1/9) at 12 months (P<.05). Most striking, however, was the incidence of long-term gastrostomy, with 78% (14/18) of patients receiving 74.4 Gy requiring gastrostomy feedings at 12 months compared with 18% (2/11) in the 60.0-Gy group (P =.002). Local control was unchanged by the altered dosing, with median follow-ups of 43.5 and 24.0 months in the 74.4-Gy and 60.0-Gy groups, respectively.

Conclusion: Decreased radiation doses can maintain disease control and reduce treatment-related long-term swallowing complications.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Combined Modality Therapy
  • Deglutition Disorders / epidemiology
  • Deglutition Disorders / etiology
  • Deglutition Disorders / prevention & control*
  • Dose Fractionation, Radiation
  • Dose-Response Relationship, Radiation
  • Female
  • Humans
  • Hydroxyurea / administration & dosage
  • Hypopharyngeal Neoplasms / mortality
  • Hypopharyngeal Neoplasms / pathology
  • Hypopharyngeal Neoplasms / radiotherapy*
  • Logistic Models
  • Male
  • Middle Aged
  • Mouth Mucosa
  • Mouth Neoplasms / mortality
  • Mouth Neoplasms / pathology
  • Mouth Neoplasms / radiotherapy*
  • New York City / epidemiology
  • Oropharyngeal Neoplasms / mortality
  • Oropharyngeal Neoplasms / pathology
  • Oropharyngeal Neoplasms / radiotherapy*
  • Prospective Studies
  • Radiotherapy / adverse effects
  • Stomatitis / epidemiology
  • Stomatitis / etiology
  • Stomatitis / prevention & control
  • Survival Analysis
  • Weight Loss

Substances

  • Antineoplastic Agents
  • Hydroxyurea